Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech - LARVOL DELTA

GI Reactogenicity Signals Following mRNA COVID-19 Vaccination in Celiac Disease and Gluten-Related Disorders: A Multi-Year VAERS Disproportionality Analysis (ACG 2026) - " Retrospective disproportionality analysis of VAERS public use data (2020â2025), restricted to mRNA vaccines (BNT162b2, mRNA-1273). Among 1,245,612 VAERS reports, 9,373 met CD/GRD cohort criteria. CD/GRD patients showed significantly elevated RORs for all target GI symptoms versus non-CD/GRD reporters. Strongest signals: abdominal distension (ROR 3.66; 95% CI 2.47â5.42), dyspepsia (ROR 2.87; 95% CI 1.86â4.44), and abdominal pain (ROR 2.82; 95% CI 2.26â3.52)."

Celiac Disease • Dyspepsia • Immunology • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 risk perception, preventive behaviors, vaccination acceptance and hesitancy, and psychosocial status in liver transplant recipients. (PubMed, Front Public Health) - "In multivariable analyses, higher SDHS scores were independently associated with middle income (p = 0.006), high income (p = 0.021), everolimus use (p = 0.041), and influence of scientific journals and official documents (p = 0.006), whereas COVID-19 infection after BNT162b2 vaccination was associated with lower SDHS scores (p = 0.004). Vaccination status and infection timing should not be interpreted as robust, mutually independent determinants of COVID-19 risk perception. These findings support reliable scientific communication, psychosocial support, and sustained engagement with transplant recipients during future infectious disease outbreaks."

Journal • CNS Disorders • Depression • Infectious Disease • Novel Coronavirus Disease • Psychiatry • Transplantation

Evaluating COVID-19 vaccine effectiveness across epidemiologic designs: test-negative case-control versus retrospective cohort analyses in a nationwide study. (PubMed, Int J Epidemiol) - "Both designs yielded consistent effectiveness estimates across vaccines and clinically relevant outcomes, with only modest differences related to handling of health-seeking behavior. These findings demonstrate that, when rigorously implemented using quality data and harmonized analytic strategies, both designs produce comparable effectiveness estimates."

Clinical • Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. (PubMed, Br J Haematol) - P3 | "COVID-19 vaccines (BNT162b2 or ChAdOx1) were administered before, during or after cytoreductive treatment comprising rituximab (depletes B cells) and either bendamustine (depletes CD4+ T cells) or cyclophosphamide-based chemotherapy. Several clinical scenarios were identified where dichotomous immune responses were estimated with >95% confidence based on combinations of predictive variables. In conclusion, the immunogenicity of COVID-19 vaccines in FL patients is influenced by multiple disease- and treatment-related factors, among which B-cell depletion showed differential effects on antibody and T-cell responses."

Journal • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Novel Coronavirus Disease • Oncology • Respiratory Diseases • CD4 • IFNG

Late Breaking Abstract - LP.8.1-adapted BNT162b2 COVID-19 vaccine effectiveness against hospitalization in Spain using the id.DRIVE platform during the 2025–2026 season (ERS 2026) - "LP.8.1-adapted BNT162b2 was highly effective against COVID-19 hospitalization among adults in Spain. Further study of COVID-19 VE is needed to better understand VE and duration of protection in risk groups."

Clinical • Late-breaking abstract • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Metabolic health indices and insulin resistance are independent determinants of SARS-CoV-2 vaccine–induced humoral immunity (ERS 2026) - " In this cross-sectional study, 198 healthcare workers (mean age 47.7±11.6 years) vaccinated with two or three doses of the BNT162b2 mRNA vaccine were evaluated 4–6 months post-vaccination... Metabolic health, particularly insulin resistance as captured by composite metabolic indices, is independently associated with SARS-CoV-2 vaccine–induced humoral immunity."

Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Obesity • Respiratory Diseases

Long-COVID syndrome and vaccination protection – a prospective study analysis (ERS 2026) - "Most of the individuals received two doses (58.5%), predominantly Comirnaty® (Pfizer), followed by Vaxzevria® (AstraZeneca)...No significant differences were observed with fatigue, however, lower scores were seen with with Janssen® alone (mean 9.0) and Janssen® plus Spikevax® (Moderna) (mean 9.5), whereas Pfizer regimens showed higher scores (mean 22). Our study supports the effectiveness of the vaccine protecting against acute infection severity, but it also shows a tendency in reducing respiratory symptom burden in Long-COVID, reinforcing its protective role beyond the acute phase."

Clinical • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients (clinicaltrials.gov) - P2 | N=56 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center | Initiation date: Sep 2026 ➔ Dec 2026

Trial initiation date • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Novel Coronavirus Disease • Oncology • Transplantation

Diminished TCF-1 expression following hematopoietic stem cell transplantation impairs T cell responses to vaccination (TTS 2026) - " POTENCy was a prospective, single-center, observational study comparing responses to BNT162b2 mRNA vaccination in allo-HSCT recipients (N=20) and age- and sex-matched healthy controls (N=20)... Allo-HSCT recipients display a global reduction in TCF-1 expression associated with diminished T cell stemness and impaired central memory formation following vaccination. These findings demonstrate a potential mechanism of impaired vaccine-induced cellular immunity after HSCT, with implications for strategies to enhance long-term immune protection in transplant recipients."

Bone Marrow Transplantation • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation • CD4 • CD8 • CX3CR1 • GZMB

C4591059: Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data (clinicaltrials.gov) - P=N/A | N=1 | Terminated | Sponsor: Pfizer | Completed ➔ Terminated; Study discontinued due to questions of data validity and bias in data which would limit causal inference and estimation of vaccine effectiveness.

Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-based Variant-adapted Vaccine Candidate (LP.8.1) against SARS-CoV-2 in Participants 12 through 64 Years of Age Considered at Higher Risk of Severe COVID-19 and Participants ≥ 65 Years of Age (IDWeek 2026) - No abstract available

Clinical • P3 data • Infectious Disease • Novel Coronavirus Disease

Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 vaccines against COVID-19–related hospitalizations and medically attended COVID-19 among adults aged ≥ 65 years in the United States (IDWeek 2026) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry. (PubMed, J Transl Med) - "Our results describe for the first time the TCR CDR3αβ motifs amplified or de novo expanded by induction with a viral antigen showing a molecular mimicry with a tumor antigen. They are strictly individual and do not match with any motif in the publicly available TCR repository. However, considering the significant degeneracy in the TCR binding to the same epitope, the finding of identical TCR CDR3αβ motifs elicited by two homologous epitopes is of the highest functional relevance. Such results provide a clear experimental validation proof that microbial epitopes mimicking TAAs can be used to develop off-the-shelf preventive/therapeutic vaccine formulations. Indeed, such non-self antigens are much stronger immunogens and may elicit a potent cross-reacting anti-cancer T cell response."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • CD8

Assessment of the immune response induced by ChAdOx1 nCoV-19 Oxford-AstraZeneca, Sputnik V, and BNT162b2 Pfizer-BioNTech vaccines during the COVID-19 epidemic outbreak in the Mexican population: Gene expression of the cytokine storm. (PubMed, Infect Genet Evol) - "Longitudinal studies with appropriate controls are needed to establish the biological significance of these transcriptional patterns."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD79A • FCGR3A • IL10 • IL2

Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Everest Medicines (Singapore) Pte. Ltd. | N=3800 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (clinicaltrials.gov) - P1/2 | N=368 | Active, not recruiting | Sponsor: SK Bioscience Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • IL4

Rare Complete Restoration of Intraepidermal Nerve Fibre Density by Immunoglobulins in Post-COVID Vaccination Syndrome-Associated Small Fibre Neuropathy: A Case Report and Literature Review. (PubMed, Cureus) - "The patient was a 53-year-old woman who developed SFN in June 2021 following her second BNT162b2 vaccination...Treatment with IVIG over several months led to an improvement in symptoms and a complete restoration of IENFD. This case highlights the importance of diagnosing PACVS-associated SFN and the beneficial effect of IVIG, which not only improves the clinical manifestations of SFN but also normalises IENFD."

Journal • Cardiovascular • Hypotension • Infectious Disease • Novel Coronavirus Disease • Pain

mFLUSIVA - an mRNA-based influenza vaccine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults. (PubMed, Vaccine) - "Reactogenicity events were common but rarely severe. Although reactogenicity appeared less frequent following Nvx than mRNA vaccines within strata, the trial was not powered for between-vaccine comparisons and findings should be interpreted descriptively."

Journal • Fatigue • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain

Age-specific humoral immune response to SARS-CoV-2: A comparative analysis of antibody levels in children and adults after vaccination with primary series or infection. (PubMed, PLoS One) - "COVID-19 immune responses differ between children and adults, with adolescents exhibiting stronger immune response to vaccination than children younger than 12, however vaccine dosage may play a role in this observed difference. Age-related differences after infection were limited to S2 antibody responses."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study of COVID-19 Vaccine(s) in Children and Adults (clinicaltrials.gov) - P3 | N=700 | Not yet recruiting | Sponsor: BioNTech SE

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Long-term adverse effects following COVID-19 vaccination: A comparative analysis of Oxford AstraZeneca, Pfizer-BioNTech, and Moderna vaccines. (PubMed, Medicine (Baltimore)) - "This study aimed to investigate long-term adverse clinical symptoms following COVID-19 vaccination with the Oxford AstraZeneca (ChAdOx1 nCoV-19, Oxford), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines. In conclusion, the most commonly reported long-term adverse effects after COVID-19 vaccination were chronic fatigue, cognitive impairment, and menstrual irregularity. Further large-scale studies are required to provide more conclusive evidence."

Clinical • Journal • Alzheimer's Disease • Cognitive Disorders • Fatigue • Infectious Disease • Novel Coronavirus Disease • Women's Health

Effectiveness of COVID-19 vaccination schedules against severe COVID-19 in children aged 6 months to 4 years in Brazil: A population-based cohort study (2023-2024). (PubMed, Vaccine) - "In this population-based cohort, completion of the 3-dose BNT162b2 primary series was associated with substantially lower rates of COVID-19-attributed SARI among children aged 6 months to 4 years."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Stroke risk following BNT162b2 vaccination: a systematic review and meta-analysis of self-controlled case series studies. (PubMed, Expert Rev Vaccines) - "These findings provide no evidence of increased short-term stroke risk following BNT162b2 vaccination at the population level. The observed heterogeneity appeared to be partly driven by methodological differences rather than true biological variation in vaccine effect."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

Pfizer…and BioNTech SE..announced today that the…FDA has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years (Businesswire) - "The FDA approval is based on the cumulative body of evidence previously submitted by Pfizer and BioNTech that includes clinical, non-clinical and real-world data supporting the safety and effectiveness of COMIRNATY, as well as manufacturing/quality and non-clinical data showing that the XFG-adapted COVID-19 vaccine generated strong immune responses against currently circulating SARS-CoV-2 variants, including XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 and other contemporary lineages."

FDA approval • Infectious Disease • Novel Coronavirus Disease